摘要
目的探讨四种肿瘤标记物血清甲胎蛋白(AFP)、血清α-L-岩藻糖苷酶(AFU)、非特异性肿瘤相关糖类抗原(CA19-9)和γ-谷氨酰转肽酶(γ-CGT)联合检验在原发性肝癌诊断中的价值。方法对63例原发性肝癌患者、42例良性肝病患者和54例健康体检者的血清AFP、AFU、CA19-9和γ-CGT水平进行测定。结果 AFP、AFU、CA19-9和γ-CGT对原发性肝癌的单项检测灵敏性分别为81.0%、76.2%、71.4%和65.1%,四项联合检测对原发性肝癌诊断的灵敏性提高至92.1%,比每一种单项检测都显著增高(P<0.05)。结论多种肿瘤标记物联合检测可明显提高原发性肝癌诊断的灵敏性,弥补单项检测的不足,有助于原发性肝癌的筛查和诊断。
Objective To explore the possible clinical value of tumor-marker co-detection in diag- nosing primary hepatic carcinoma by co-detecting the serum levels of AFP, AFU, CA19-9 and ~,-CGT in pa- tients with primary hepatic carcinoma. Methods 63 cases of primary hepatic carcinoma, 42 cases of be- nign liver diseases and 54 cases of healthy individuals were assessed for serum levels of AFP, AFU, CA199 and 3,-CGT. Results The individual detection sensitivities for AFP, AFU, CA199 and ~/-CGT were 81.0%, 76. 2% ,71.4% and 65. 1% respectively. But the co-detection sensitivity was 92. 1%, showing a significant elevation as compared to any of the individual detection sensitivities （P 〈 O. 05）. Conclusion Co-detec- tion of tumor-marker significantly enhances the detection sensitivity in diagnosing primary hepatic carcino- ma, compensates for the insufficiency of individual detection and is of importance in clinical screening and diagnosis of primary hepatic carcinoma.
出处
《中国肿瘤临床与康复》
2013年第9期941-943,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
肝肿瘤
联合检验
肿瘤标记物
Hepatic neoplasms
Co-detection
Tumor-marker
